Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors
Clinical Colorectal Cancer · 2026
DOI: 10.1016/j.clcc.2026.05.003 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Colorectal Cancer, 2026. Verfasst von Lea Jehanno und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Immune checkpoint inhibitors (ICI) are standard for MSI-H/dMMR metastatic colorectal cancer (mCRC). We compared their efficacy and sought subgroups deriving greater benefit from ICI combination. PATIENTS AND METHODS: All patients with MSI/dMMR mCRC treated by anti-PD-1 ± anti-CTLA-4 in the prospective monocenter immunoMSI cohort were analyzed. Treatment choice followed trials availability and regulatory approvals. Main endpoints were progression-free survival (PFS, iRECIST) and overall survival (OS). Landmark analysis at 6 months, restricted mean survival time (τ = 7 years) and piecewise Cox models were used. Interactions were tested in a single Cox model including subgroup terms, treatment, and interaction terms. RESULTS: Among 210 patients, 97 received ICI combination and 113 monotherapy with anti-PD-1. Median follow-up was 4.4 years (4.1 combo; 5.4 mono). About 165 patients (78.5%) received ICI in second line or latter. Combination improved PFS (hazard ratios [HR] 0.48, 95% CI 0.31-0.76) and OS (HR 0.49, 0.29-0.84). RMST was 5.27 versus 3.91 years (+1.36 years, 0.55-2.17). Piecewise HRs showed an early benefit (0-6 months HR 0.32, 0.16-0.66) that attenuated thereafter. Objective responses were 78% versus 60%; progressive disease 5% versus 15%. Interactions were observed for sex (PFS HR 0.21 vs. 0.87 for females vs. males; P-interaction = .0067), liver metastases (0.30 vs. 0.79; 0.0479) and sidedness (0.27 vs. 0.64; 0.0922). CONCLUSION: Dual CTLA-4/PD-1 blockade improved PFS and OS versus anti-PD-1 alone, driven by higher early response rates. Female sex, absence of liver metastases, and left-sided tumor location may predict greater benefit from combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France.
- Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France; EFS, Université Marie et Louis Pasteur, Besançon, France.
- Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.
- Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France; Sorbonne University, INSERM, Unité Mixte de Recherche Scientifique 938 and SIRIC CURAMUS, Centre de Recherche Saint-Anto…
- Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France; Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France; EFS, Université Mar…
Zitieren
APA
Jehanno, L., Henriques, J., Samaille, T., Loisel, C., Cervantes, B., Colle, R., Vernerey, D., André, T., & Cohen, R. (2026). Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.05.003
Vancouver
Jehanno L, Henriques J, Samaille T, Loisel C, Cervantes B, Colle R, et al. Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.05.003
BibTeX
@article{Jehanno2026,
author = {Jehanno, Lea and Henriques, Julie and Samaille, Thomas and Loisel, Camille and Cervantes, Baptiste and Colle, Raphaël and Vernerey, Dewi and André, Thierry and Cohen, Romain},
title = {Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors},
journal = {Clinical Colorectal Cancer},
year = {2026},
doi = {10.1016/j.clcc.2026.05.003}
}
EUVIMED